Company OverviewAIkido Pharma Inc.
AIkido Pharma Inc. (NASDAQ: AIKI) was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore .
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.
The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Speaker BioVice President and General Counsel
Aikido Pharma Inc.
Darrell Dotson has been with Aikido since 2013. He is a registered patent attorney and has B.S. degrees in both biology and zoology from Texas A&M University, a Ph.D. in biochemistry and molecular biology from the University of Texas Health Science Center in Houston, Texas, and a law degree from The University of Houston Law Center, graduating cum laude. For two decades, he specialized in patent litigation and licensing with a primary emphasis on cases involving biotechnology or pharmaceutical inventions. Currently, he has a lead role at Aikido in evaluating and licensing pharmaceutical inventions for development by the Company and overseeing the development of Aikido’s pipeline.
Contact Us
Website:
https://ir.aikidopharma.com/
Email:
info@aikidopharma.com
Phone Number:
(212) 745-1374
